OBJECTIVE: To review the evidence on the efficacy and safety of pharmacologic and nonpharmacologic therapies for smoking cessation. QUALITY OF EVIDENCE: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched for randomized controlled trials, meta-analyses, and systematic reviews (level I evidence) pertinent to pharmacologic and nonpharmacologic smoking cessation therapies. MAIN MESSAGE: Pharmacologic smoking cessation aids are recommended for all smokers trying to quit, unless contraindicated. A new pharmacologic smoking cessation aid, varenicline, is now available in Canada. Level I evidence at 1-year follow-up indicates that it is effective for smoking cessation. Adverse effects include nausea, insomnia, and abnormal dreaming. Nausea is mild or moderate and decreases over time. Varenicline is more effective than placebo or bupropion. Counseling also increases the likelihood of achieving cessation. CONCLUSION: Preliminary data indicate that varenicline is more effective than other available pharmacologic smoking cessation aids. Pharmacologic therapy should be combined with nonpharmacologic therapy.
OBJECTIVE: To review the evidence on the efficacy and safety of pharmacologic and nonpharmacologic therapies for smoking cessation. QUALITY OF EVIDENCE: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched for randomized controlled trials, meta-analyses, and systematic reviews (level I evidence) pertinent to pharmacologic and nonpharmacologic smoking cessation therapies. MAIN MESSAGE: Pharmacologic smoking cessation aids are recommended for all smokers trying to quit, unless contraindicated. A new pharmacologic smoking cessation aid, varenicline, is now available in Canada. Level I evidence at 1-year follow-up indicates that it is effective for smoking cessation. Adverse effects include nausea, insomnia, and abnormal dreaming. Nausea is mild or moderate and decreases over time. Varenicline is more effective than placebo or bupropion. Counseling also increases the likelihood of achieving cessation. CONCLUSION: Preliminary data indicate that varenicline is more effective than other available pharmacologic smoking cessation aids. Pharmacologic therapy should be combined with nonpharmacologic therapy.
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Cheryl Oncken; David Gonzales; Mitchell Nides; Stephen Rennard; Eric Watsky; Clare B Billing; Richard Anziano; Karen Reeves Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Sandra A Mitchell; Cheryl A Fisher; Clare E Hastings; Leanne B Silverman; Gwenyth R Wallen Journal: Nurs Outlook Date: 2010 Nov-Dec Impact factor: 3.250
Authors: A Batra; K U Petersen; E Hoch; K Mann; C Kröger; C Schweizer; A Jähne; T Rüther; N Thürauf; S Mühlig Journal: Nervenarzt Date: 2016-01 Impact factor: 1.214
Authors: Bach Xuan Tran; Mackenzie Moir; Carl A Latkin; Brian J Hall; Cuong Tat Nguyen; Giang Hai Ha; Nam Ba Nguyen; Cyrus S H Ho; Roger C M Ho Journal: Subst Abuse Treat Prev Policy Date: 2019-05-17